Effects of Eicosapentaenoil acid rich Fish Oil on Exercise economy in patients with Cardiovascular Diseases

Effects of Eicosapentaenoil acid rich Fish Oil on Exercise economy in patients with Cardiovascular Diseases - Effects of Eicosapentaenoil acid rich Fish Oil on Exercise economy in patients with Cardiovascular Diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000023423

Enrollment

Registered

2016-08-01

Start date

2016-07-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart disorder

Interventions

EPA 900mg/day placebo

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Less than LVEF40% or BNP 80pg/ml more 2)chronic heart failure patients or poat PCI with acute coronary syndrome patients

Exclusion criteria

Exclusion criteria: 1)Recent cerebrovascular event within 3 months 2)Acute heart failure 3)Less than eGFR30 4)NOAC or Warfarin

Design outcomes

Primary

Measure	Time frame
It is the same extreme(60% of the load at the maximum oxygen intake at CPX before beginning of dosage) oxygen intake at Cardiopulmonary Exercise Test(CPX) as of 12 weeks and a difference from the baseline after beginning of dosage	—

Secondary

Measure	Time frame
An effective evaluation:It is the echocardiography evaluation as of at 12 weeks and 24 weeks, a fluidity of blood evaluation, drawing blood (CBC, lipid-based system, hsCRP, EPA/AA), quality of life questionary survey, an oxidative stress degree by the d-ROMs test after beginning of dosage. It is the same extreme oxygen intake at CPX as of 24 weeks and a difference from the baseline after beginning of dosage Safety assessment:Adverse event (bleeding tendency in particular, examination for peripheral blood (oligochromemia, leukopenia, thrombocytopenia, incidence) of high TG blood disease)	—

Measure

Time frame

An effective evaluation:It is the echocardiography evaluation as of at 12 weeks and 24 weeks, a fluidity of blood evaluation, drawing blood (CBC, lipid-based system, hsCRP, EPA/AA), quality of life questionary survey, an oxidative stress degree by the d-ROMs test after beginning of dosage. It is the same extreme oxygen intake at CPX as of 24 weeks and a difference from the baseline after beginning of dosage Safety assessment:Adverse event (bleeding tendency in particular, examination for peripheral blood (oligochromemia, leukopenia, thrombocytopenia, incidence) of high TG blood disease)

—

Countries

Japan

Contacts

Public ContactAkiko Niijima

Dokkyo Medical University Nikko Medical Center Clinical Research Support Center

aniijima@dokkyomed.ac.jp0288-76-1515

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026